Author

M. M. Allevato

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

J. S. Gutkind· 3 shared Z. Wang· 3 shared A. A. Molinolo· 2 shared E. E. W. Cohen· 2 shared V. H. Wu· 2 shared Y. Goto· 2 shared A. B. Sharabi· 1 shared A. B. Simon· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. S. Gutkind

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A kinome-wide synthetic lethal CRISPR/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4/CDK6 blockade in HNSCC

Y. Goto, K. Koshizuka, T. Ando, H. Izumi, X. Wu, K. Ford, X. Feng, Z. Wang, N. Arang, M. M. Allevato, A. Kishore, P. Mali, J. S. Gutkind

This study identifies mTOR inhibition as a way to prevent adaptive resistance to CDK4/6 blockade in HNSCC by targeting cell cycle pathways.

bioRxiv · Aug 7, 2023Cancer Biology

Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC

R. Saddawi-Konefka, A. O'Farrell, F. Faraji, L. Clubb, M. M. Allevato, N.-A. A. S. Anang, S. M. Jensen, Z. Wang, V. H. Wu, B. S. Yung, R. Al Msari, I. Franiak Pietryga, A. A. Molinolo, J. P. Mesirov, A. B. Simon, , J. S. Gutkind

This study shows that lymphatic-preserving treatment sequences enhance cDC1-dependent antitumor immunity in HNSCC by avoiding lymphablation, which compromises ICI response.

bioRxiv · Feb 1, 2022Cancer Biology

Novel syngeneic animal model of tobacco-associated oral cancer reveals the activity of in situ anti-CTLA-4

Z. Wang, V. H. Wu, M. M. Allevato, M. Gilardi, Y. He, J. L. Callejas-Valera, L. Vitale-Cross, D. Martin, P. Amornphimoltham, J. Mcdermott, Y. Goto, A. A. Molinolo, A. B. Sharabi, E. E. W. Cohen, Q. Chen, , J. S. Gutkind

This paper develops a syngeneic mouse model of tobacco-associated HNSCC that shows high response rates to anti-CTLA-4 therapy.

bioRxiv · Jun 15, 2019 · PreprintCancer Biology